ACG Wealth’s ANI Pharmaceuticals ANIP Stock Holding History

ACG Wealth’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	279
2022 Q2	$0	Buy	+1	New	+$29	﹤0.01%	911

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

ACG Wealth's ANIP Position: Q3 2022 in Review

ACG Wealth sold out of ANI Pharmaceuticals (ANIP) in Q3 2022, closing a stake of 1 share.

ACG Wealth first reported a position in ANIP in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 126 funds tracked by Wall St. Rank hold ANIP as of Q3 2022.

ACG Wealth reported no remaining ANI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 1 ANI Pharmaceuticals share in Q3 2022.
ACG Wealth first reported a position in ANI Pharmaceuticals in Q2 2022 and held it in 1 quarter.
ACG Wealth's ANI Pharmaceuticals position peaked at $0 in Q2 2022.
126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.